The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Specialty Chemicals grew 38% YoY for FY23
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Company is investing more than €100 million in the expansion of the Halle site
Subscribe To Our Newsletter & Stay Updated
